%A Zhang,Jingcheng %A Cao,Zhe %A Yang,Gang %A You,Lei %A Zhang,Taiping %A Zhao,Yupei %D 2019 %J Frontiers in Oncology %C %F %G English %K microRNA,MicroRNA-27a,Signaling Pathways,biomarker,clinical application %Q %R 10.3389/fonc.2019.00893 %W %L %M %P %7 %8 2019-September-12 %9 Review %# %! MicroRNA-27a (miR-27a) in solid tumors: a review based on mechanisms and clinical observations %* %< %T MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations %U https://www.frontiersin.org/articles/10.3389/fonc.2019.00893 %V 9 %0 JOURNAL ARTICLE %@ 2234-943X %X MicroRNAs (miRNAs) are a family of highly conserved, non-coding single-stranded RNAs transcribed as ~70 nucleotide precursors to an 18–22 nucleotide product (1). miRNAs can silence their homologous target genes at the post-transcriptional level, and these genes have been revealed to play an important role in tumorigenesis, invasion and metastasis (2). MicroRNA-27a (miR-27a), transcripted by miR-27a gene, has proved to implicate with many kinds of solid tumors, showing potential as a useful biomarker or drug target for clinical application. However, even though miR-27a has been reported in many cancers, the mechanism and signal pathways of miR-27 in oncogenesis, invasion, and metastasis are still obscure. Moreover, recent studies show that miR-27a pays an important role in epithelial-mesenchymal-transition, regulating tumor immune response, and chemoresistance. In this review, we summarize the current literature, demonstrate the established link between miR-27a and tumorigenesis, and focus on recently identified mechanisms. The review also aims to demonstrate the potential of miR-27a as a diagnostic and/or prognostic biomarker in solid tumors and to discuss the possibilities of targeted therapy and drug design.